GLP-1 vs GLP-1/GIP Dual Agonist Research: What the GIP Receptor Adds

GLP-1 receptor agonists activate one incretin receptor; unimolecular dual agonists activate both GLP-1R and GIPR with one peptide. The research literature reports effects of dual agonism on food preference, thermogenesis and metabolic markers that differ from GLP-1 agonism alone, and receptor-crosstalk studies are now examining why. APX Labs supplies one research pen of each class. Neither is a drug product.

The incretin system

Incretins are gut hormones released after eating that amplify glucose-dependent insulin secretion. There are two: glucagon-like peptide-1 (GLP-1), from intestinal L-cells, and glucose-dependent insulinotropic polypeptide (GIP), from K-cells. Both are cleaved within minutes by the enzyme DPP-IV, which is why synthetic long-acting analogs exist. The physiology of GLP-1 is reviewed in Holst's *Physiological Reviews* article [1] and the whole proglucagon-derived family in a 2026 update [2].

GLP-1 receptor agonists

GLP-1R agonists are analogs of GLP-1 engineered to resist DPP-IV — through amino-acid substitutions, fatty-acid side chains that bind albumin, or both — extending half-life from minutes to days. Drucker's *Cell Metabolism* review is the reference for their mechanisms of action [3]: potentiated insulin secretion, suppressed glucagon, slowed gastric emptying, and central effects on appetite pathways. More recent work examines anti-inflammatory actions beyond the metabolic ones [4]. GLP1-R supplies an agonist of this class in a research format.

Dual GLP-1/GIP agonists

For years GIP was considered the weaker incretin. That changed with unimolecular co-agonists — single peptides engineered to activate both receptors. In rodent research, a dual agonist selectively reduced preference for fat [5] and produced a thermogenic-like signature in brown adipose tissue [6]; plasma-proteome profiling has been used to characterise dual agonism's effects [7]. Receptor-level work is now examining how GLP-1R and GIPR signalling interact [8]. GLP1-T supplies a dual agonist of this class in a research format.

What the GIP component adds — in the literature

• Food intake and preference models: effects on macronutrient preference not seen with GLP-1 agonism alone [5]
• Energy expenditure models: thermogenic signatures in adipose tissue [6]
• Receptor crosstalk: evidence that co-activation modulates insulinotropic signalling differently from either receptor alone [8]
• The direction of the field: triple agonists adding glucagon-receptor activity [9] and GIPR-selective long-acting agonists [10]

Specifications side by side

• Receptors: GLP1-R → GLP-1R only · GLP1-T → GLP-1R + GIPR
• Molecular weight: 4113.6 g/mol · 4813.5 g/mol
• Format: pre-filled research pen, 40 mg, both
• Testing: independent HPLC/MS, batch COA, both
• Price: GLP1-R $319 · GLP1-T $299

These pens are research reagents. They are not the prescription GLP-1 or dual-agonist medications, are not manufactured or approved for human use, and the literature above describes research on the drug class — not claims about these products. Research use only.

Frequently asked